Compare Johnson & Johnson (JNJ) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Under Armour Inc Class A — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: Johnson & Johnson is far larger — about 298.6× Under Armour Inc Class A's market cap, and Johnson & Johnson pays a 2.09% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Under Armour Inc Class A for 18 Days on average.
| JNJ | UA | |
|---|---|---|
Market Cap | $618.09B | $2.07B |
Volume | 6,050,983 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $7.88 |
52-Week Low | $186.00 | $3.96 |
Typical Hold Time | 129 Days | 18 Days |
Enterprise Value | $646.37B | $3.05B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Under Armour (UA) trades at $4.74, up 0.85% with a bullish technical signal despite mixed earnings. The company faces revenue declines and negative profitability with a -9.99% net margin, though valuation metrics like P/S of 0.41 appear attractive. Recent Q2 2026 earnings beat expectations, but guidance has been lowered amid softer consumer demand.
Outlook remains challenging with significant cash burn and competitive pressures. While analyst sentiment is mixed with 39.7% buy ratings, the stock offers speculative value for turnaround investors willing to bear execution risks and ongoing revenue headwinds in the athletic apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
